vs

Side-by-side financial comparison of AVITA Medical, Inc. (RCEL) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

USCB FINANCIAL HOLDINGS, INC. is the larger business by last-quarter revenue ($22.2M vs $17.6M, roughly 1.3× AVITA Medical, Inc.). USCB FINANCIAL HOLDINGS, INC. runs the higher net margin — 6.1% vs -66.0%, a 72.1% gap on every dollar of revenue. On growth, USCB FINANCIAL HOLDINGS, INC. posted the faster year-over-year revenue change (14.7% vs -4.3%). USCB FINANCIAL HOLDINGS, INC. produced more free cash flow last quarter ($42.5M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 12.3%).

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

RCEL vs USCB — Head-to-Head

Bigger by revenue
USCB
USCB
1.3× larger
USCB
$22.2M
$17.6M
RCEL
Growing faster (revenue YoY)
USCB
USCB
+19.0% gap
USCB
14.7%
-4.3%
RCEL
Higher net margin
USCB
USCB
72.1% more per $
USCB
6.1%
-66.0%
RCEL
More free cash flow
USCB
USCB
$48.6M more FCF
USCB
$42.5M
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
12.3%
USCB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RCEL
RCEL
USCB
USCB
Revenue
$17.6M
$22.2M
Net Profit
$-11.6M
$1.4M
Gross Margin
81.2%
Operating Margin
-59.1%
14.7%
Net Margin
-66.0%
6.1%
Revenue YoY
-4.3%
14.7%
Net Profit YoY
-0.3%
-80.3%
EPS (diluted)
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RCEL
RCEL
USCB
USCB
Q4 25
$17.6M
$22.2M
Q3 25
$17.1M
$25.0M
Q2 25
$18.4M
$24.4M
Q1 25
$18.5M
$22.8M
Q4 24
$18.4M
$23.0M
Q3 24
$19.5M
$21.5M
Q2 24
$15.2M
$20.5M
Q1 24
$11.1M
$17.6M
Net Profit
RCEL
RCEL
USCB
USCB
Q4 25
$-11.6M
$1.4M
Q3 25
$-13.2M
$8.9M
Q2 25
$-9.9M
$8.1M
Q1 25
$-13.9M
$7.7M
Q4 24
$-11.6M
$6.9M
Q3 24
$-16.2M
$6.9M
Q2 24
$-15.4M
$6.2M
Q1 24
$-18.7M
$4.6M
Gross Margin
RCEL
RCEL
USCB
USCB
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Q1 24
86.4%
Operating Margin
RCEL
RCEL
USCB
USCB
Q4 25
-59.1%
14.7%
Q3 25
-53.6%
47.3%
Q2 25
-60.5%
44.0%
Q1 25
-63.9%
44.2%
Q4 24
-54.1%
39.6%
Q3 24
-70.6%
42.5%
Q2 24
-102.8%
39.8%
Q1 24
-155.0%
34.3%
Net Margin
RCEL
RCEL
USCB
USCB
Q4 25
-66.0%
6.1%
Q3 25
-77.3%
35.8%
Q2 25
-53.9%
33.4%
Q1 25
-74.9%
33.5%
Q4 24
-63.0%
30.0%
Q3 24
-82.9%
32.3%
Q2 24
-101.3%
30.3%
Q1 24
-168.0%
26.2%
EPS (diluted)
RCEL
RCEL
USCB
USCB
Q4 25
$-0.37
Q3 25
$-0.46
$0.45
Q2 25
$-0.38
Q1 25
$-0.53
Q4 24
$-0.44
Q3 24
$-0.62
$0.35
Q2 24
$-0.60
Q1 24
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RCEL
RCEL
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$18.2M
$38.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$-16.6M
$217.2M
Total Assets
$56.4M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RCEL
RCEL
USCB
USCB
Q4 25
$18.2M
$38.5M
Q3 25
$23.3M
$56.8M
Q2 25
$15.7M
$54.8M
Q1 25
$25.8M
$98.0M
Q4 24
$35.9M
$77.0M
Q3 24
$44.4M
$38.5M
Q2 24
$54.1M
$77.3M
Q1 24
$68.2M
$126.5M
Stockholders' Equity
RCEL
RCEL
USCB
USCB
Q4 25
$-16.6M
$217.2M
Q3 25
$-6.7M
$209.1M
Q2 25
$-12.9M
$231.6M
Q1 25
$-4.6M
$225.1M
Q4 24
$4.5M
$215.4M
Q3 24
$12.2M
$213.9M
Q2 24
$23.9M
$201.0M
Q1 24
$32.6M
$195.0M
Total Assets
RCEL
RCEL
USCB
USCB
Q4 25
$56.4M
$2.8B
Q3 25
$63.7M
$2.8B
Q2 25
$58.1M
$2.7B
Q1 25
$69.6M
$2.7B
Q4 24
$79.7M
$2.6B
Q3 24
$81.1M
$2.5B
Q2 24
$87.8M
$2.5B
Q1 24
$97.4M
$2.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RCEL
RCEL
USCB
USCB
Operating Cash FlowLast quarter
$-5.4M
$42.8M
Free Cash FlowOCF − Capex
$-6.1M
$42.5M
FCF MarginFCF / Revenue
-34.7%
191.4%
Capex IntensityCapex / Revenue
3.8%
1.4%
Cash ConversionOCF / Net Profit
31.40×
TTM Free Cash FlowTrailing 4 quarters
$-33.5M
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RCEL
RCEL
USCB
USCB
Q4 25
$-5.4M
$42.8M
Q3 25
$-5.2M
$20.1M
Q2 25
$-10.2M
$18.0M
Q1 25
$-10.3M
$14.6M
Q4 24
$-8.1M
$34.8M
Q3 24
$-7.2M
$11.3M
Q2 24
$-12.8M
$18.3M
Q1 24
$-20.9M
$8.1M
Free Cash Flow
RCEL
RCEL
USCB
USCB
Q4 25
$-6.1M
$42.5M
Q3 25
$-6.2M
$20.0M
Q2 25
$-10.8M
$18.0M
Q1 25
$-10.5M
$14.6M
Q4 24
$-9.7M
$34.5M
Q3 24
$-11.0M
$11.2M
Q2 24
$-15.4M
$18.2M
Q1 24
$-22.0M
$8.0M
FCF Margin
RCEL
RCEL
USCB
USCB
Q4 25
-34.7%
191.4%
Q3 25
-36.1%
80.3%
Q2 25
-58.4%
73.7%
Q1 25
-56.9%
63.9%
Q4 24
-52.7%
150.2%
Q3 24
-56.1%
52.2%
Q2 24
-101.6%
88.8%
Q1 24
-198.2%
45.4%
Capex Intensity
RCEL
RCEL
USCB
USCB
Q4 25
3.8%
1.4%
Q3 25
5.5%
0.5%
Q2 25
2.8%
0.2%
Q1 25
1.2%
0.2%
Q4 24
8.8%
1.4%
Q3 24
19.2%
0.4%
Q2 24
17.5%
0.4%
Q1 24
10.3%
0.5%
Cash Conversion
RCEL
RCEL
USCB
USCB
Q4 25
31.40×
Q3 25
2.25×
Q2 25
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
1.63×
Q2 24
2.95×
Q1 24
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons